Sign in
CompletedPhase 2

Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A

Key facts

Who runs it
Guangdong Raynovent Biotech Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
72 people enrolled
Started
30 Nov 2024
Ended
31 Jul 2025
Type of study
Interventional, 2 groups
Treatments tested
  • ZSP1273 granules
Record updated
17 November 2025

Who can take part

Age
2 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Subjects and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately
  • Male or female subjects aged ≥ 2 to ≤17 years at the time of signing the informed consent form
  • Subjects with a diagnosis of influenza virus infection confirmed by all of the following:; Positive rapid antigen test (RAT) for influenza with nasal or throat swabs; The time interval between the onset of symptoms and enrollment is 72 hours or less; Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present

Who cannot take part

  • Subjects with any medical history in gastrointestinal that interferes with the absorption of drugs;
  • Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment;
  • Have received any other investigational products within 3 months prior to dosing;
  • Subjects with concurrent infections requiring antimicrobial therapy;
  • Subjects with severe influenza virus infection;
  • Positive urine pregnancy test;
  • Subjects who are considered inappropriate for the study by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial is conducted in China. The aim of the trial is to investigate safety,pharmacokinetics and pharmacodynamics of ZSP1273 granules

The 2 groups in the trial

  • ZSP1273(Arm a)Treatment being tested

    * ≥2 ,\<6 year old,dose 1 QD;5day * ≥6 ,\<12 year old,dose 2 QD;5day * ≥12,≤17 year old,dose 3 QD;5day

    Treatment: ZSP1273 granules

  • ZSP1273(Arm b)Treatment being tested

    * ≥2 ,\<6 year old,dose 4 QD;5day * ≥6 ,\<12 year old,dose 5 QD;5day * ≥12,≤17 year old,dose 6 QD;5day

    Treatment: ZSP1273 granules

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Open-label Phase 2 Study of ZSP1273 in Otherwise Healthy Children 2-17 Years Old With Influenza A
Publications
Record updated
17 November 2025